CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||50 mg and 100 mg|
|Indication||Acute Myeloid Leukemia (AML)|
|Funding Request||For the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation|
|Pre Noc Submission||No|
|NOC Date||February 6, 2019|
|Submission Date||April 5, 2019|
|Submission Deemed Complete||April 22, 2019|
|Stakeholder Input Deadline ‡||April 22, 2019|
|Check-point meeting||June 12, 2019|
|pERC Meeting||August 15, 2019|
|Initial Recommendation Issued||August 29, 2019|
|Feedback Deadline ‡||September 13, 2019|
|pERC Reconsideration Meeting||October 17, 2019|
|Final Recommendation Issued||October 31, 2019|
|Notification to Implement Issued||November 15, 2019|
|Therapeutic Area||Acute myeloid leukemia (AML)|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.